الفهرس 
Introduction & Aim of the workOnly 14 pages are availabe for public view
 |  | from | 506 |  |  |
| | | from | 506 | | |
Abstract
This study aimed to asses CD14 , CD61 and MPA in obese individuals.. This study aimed to evaluate MPA and to evaluate their association with different clinical and laboratory data.
Subjects were classified into:
•group 1 (patient group) :
•It included 60 obese individuals without comorbidities with body mass index more than 25.They were selected from hospital workers, students and individuals who seeked for slimming diet or sleeve gastrectomy. (32 female and 28 male):subdivided in to:
Subgroup Ia (Overweight) (pre obese): Included 12 subjects. BMI ranges from 25-29.9 Kg/m2.
Subgroup Ib (Class I obesity) : Included 28 subjects. BMI ranges from 30-34.9 Kg/m2.
Subgroup Ic (Class II obesity):Included 20 subjects. BMI ranges from 35-39.9 Kg/m2.
•group II (control group):
It included 20 apparently healthy individuals with body mass index from 18.5 to 25.
All the participants were matched in terms of age which ranges from 20 to 40 years.
Exclusion criteria:
1-Acute or chronic infection.
2-Acute or chronic inflammatory diseases.
3-Acute or chronic kidney diseases.
Patients were diagnosed in accordance with the BMI after being subjected to full assessment of the following;
1.History taking:
2.General Clinical examination:
a.Including weight, hight .
b.General abdominal examination
3.Laboratory investigations:
Routine investigation
(1)Complete blood count (CBC) including Hemoglobin, platelet count and white blood cell count (total and differential).
(2)Serum creatinine.
(3)Lipid profile ( HDL, LDL, TG and cholesterol).
(4)Liver function test (Albumin, AST and ALT).
(5)CRP
Special investigations:
1-Serum insulin by ELISA.
2- Assessment of CD14 and CD61 percentage by Flow Cytometry.
Regarding comparison between group I and group II it was found that:
•There were significant differences between obese and non-obese groups regarding platelet count, monocyte proportion, serum albumin and AST.
•There were no significant differences between both groups regarding ALT and S. creatinine.
•There were significance differences between obese and non-obese groups regarding LDL (Mean±SD 148.3±29.3 vs. 104.4±22.5, p<0.001), HDL (Mean±SD 39.8±8.5 vs. 45.2±4.5, p=0.008), cholesterol (Mean±SD 206.3±28.6 vs. 164.8±23.4, p<0.001).
• There were significance differences between obese and non-obese groups regarding insulin (median 15 vs. 8, p<0.001).
•There were significant differences between obese and non-obese groups regarding CD14 (median= 21.2% vs. 10%, p=0.001) and MPA (median=2 vs. 1.7, p=0.041).
•There was no significant difference as regard CD61.
•For MPA, there were a significant fair positive correlation with BMI (r= -0.489, p<0.001) and a significant fair positive correlation with Cholesterol (r= -0.255, p=0.049).
•Concerning comparison between subgroups of high BMI regarding routine laboratory data:
•There was a significant increase of AST in subgroup Ic in compared with subgroup Ib with p value 0.019. significant decrease in monocytic count in subgroup Ic compared with subgroup Ib.
•There was a significant increase in serum insulin in subgroups Ib and Ic compared with subgroup Ia. And CD61 in subgroup Ia compared with subgroup Ib and Ic, but no significant differences between subgroup Ib and Ic. According MPA there is a significant increase in Ia vs Ib and Ia vs Ic.
•There is a significant increase in CD61, MPA in overweight than normal, class I, II obesity. There is a significant increase in CD14 in high BMI regardless the degree of BMI but more higher in over weight than class I and class II obesity. There is a significant increase in MPA in high BMI than normal BMI group.
•Between males and females there were significant differences regarding CD61 and MPA (p<0.001) while there was no significant difference regarding CD14.
•This study shows that between controls and obesity classes there were significant differences regarding CD61, CD14 and MPA (p=0.013, 0.034 and <0.001, respectively).